Navigation Links
Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
Date:9/17/2007

NOVATO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has licensed to Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo) exclusive rights to data and intellectual property contained in the Kuvan(TM) (sapropterin dihydrochloride) new drug application (NDA). Asubio will use this data to supplement its current filing to the Japanese Ministry of Health, Labour and Welfare for approval of its BH4 product for the treatment of phenylketonuria (PKU) in Japan. The application is for a label extension for its current BH4 product marketed in Japan for primary BH4 deficiency. Kuvan is an investigational oral small molecule for the treatment of PKU being developed in partnership with Merck Serono, a division of Merck KGaA, Darmstadt, Germany. BH4 is the active ingredient in Kuvan.

"We have had a long-standing relationship with Asubio regarding BH4 as their early work on BH4 was important to our success in Kuvan development. We are pleased to finalize this new agreement to facilitate approval in Japan. While Asubio already holds the exclusive rights to its own data to commercialize BH4 for all indications in Japan, this new data greatly expands the clinical data set on treatment of PKU and is expected to accelerate the timing for the label extension of Asubio's current BH4 product," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.

BioMarin will receive a milestone payment for approval as well as double-digit royalties on net sales of BH4 for PKU in Japan.

About Kuvan

Kuvan is an investigational oral small molecule therapeutic for the treatment of PKU. The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe. Clinical data suggest that treatment with Kuvan results in significant red
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NorthStar signs exclusive agreement with Illinois foundation
2. Can you keep ahead of progress? An exclusive interview with Rick Smith of iNoc
3. Is Rayovac IT Nirvana? An exclusive interview with Rick Dempsey, VP of IT
4. WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2
5. WTN exclusive interview with Tom Still, Wisconsin Technology Council
6. WTN exclusive interview with Commerce Secretary Cory Nettles (part 3)
7. WTN exclusive interview with Commerce Secretary Cory Nettles (part 2)
8. WTN exclusive interview with Commerce Secretary Cory Nettles (part 1)
9. Luem Software and Trek Bicycle sign exclusive software agreement
10. WTN Exclusive Interview: Cory L. Nettles, Secretary of Commerce
11. Epics Founder Judy Faulkner Speaks on Culture, Business Beliefs, and Recruiting: WTN Exclusive Coverage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
(Date:4/30/2015)... 30, 2015 Nitto Avecia, a ... its increased capacity and production capability to serve ... variety and service fulfillment continues to drive Nitto ... process throughput capacities. , In Fall ... downstream process equipment at its Milford, MA facility, ...
(Date:4/30/2015)...  The Paul G. Allen Family Foundation announced today ... six groups of researchers with projects at the frontier ... growing mature human brain cells in the laboratory. The ... over three years.  "This new cohort ... significant because the field of neuronal maturation is at ...
(Date:4/30/2015)... , April 30, 2015 WuXi PharmaTech (Cayman) ... a leading global contract R&D services provider, today announced ... non-binding proposal letter, dated April 29, 2015, from a ... (the "Chairman"), founder, chairman and chief executive officer ... ("ABG") that proposes a transaction (the "Transaction") involving the ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... COVINA, Calif., May 16 StemCyte Inc. today announced,that ... company,overview with a focus on the StemCyte,s Indian joint ... Bhat will present during the session on "Stem ... the Art" on Saturday, May 17. His,presentation will include ...
... George Abercrombie, president,and chief executive officer, Hoffmann-La Roche ... today at a Rotary Club of Fort Worth ... businesses with challenges,unlike those anticipated with traditional emergency ... familiar with preparing for potential,disasters such as floods ...
... NEW YORK and HAIKOU, China, May 16 ... (OTC Bulletin Board: CPHI),which develops, manufactures, and ... announced today that it donated 2,million RMB ... anti- virus and anti-cold medicines to help ...
Cached Biology Technology:StemCyte Chief Scientific Officer to Present Company Overview with Focus on Indian Joint Venture at TiEcon 2008 2CEO Addresses Fort Worth Business Leaders About Developing Pandemic and Business Continuity Plans 2CEO Addresses Fort Worth Business Leaders About Developing Pandemic and Business Continuity Plans 3China Pharma Holdings, Inc. Donates Medicine for Sichuan Earthquake Relief 2
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... embryonic stem cell, which has the potential to become any ... of genes, proteins that bind DNA, and molecules that modify ... from MIT and the University of California at San Francisco ... cells into mature heart cells. The study, the first to ...
... A team of researchers that has been working ... within four years of a near-commercial-scale production level., The ... has received a $2 million National Science Foundation grant ... Devarenne, a Texas A&M AgriLife Research biochemist and collaborator ...
... ultrasound waves, MIT engineers have found a way to ... drug delivery more efficient. This technology could pave the ... to the researchers. "This could be used for ... systemic drugs and proteins such as insulin, as ...
Cached Biology News:Probing matters of the heart 2Probing matters of the heart 3Oil from algae closer to reality through studies by unique collaboration of scientists 2Oil from algae closer to reality through studies by unique collaboration of scientists 3Getting (drugs) under your skin 2Getting (drugs) under your skin 3
Request Info...
Request Info...
Prepared by multi-temperature ethanol fractionation with extensive charcoal treatment and dialysis.• Assay: ≥ 95 % (HPCE)• pH ~5.2 (10 mg/mL in 0.15 M NaCl)...
Special grade: for electrophoresis...
Biology Products: